Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action

Abstract

Generalized anxiety disorder (GAD), the most frequently diagnosed form of anxiety, is usually treated by cognitive-behavioural approaches or medication; in particular, benzodiazepines (acutely) and serotonin or serotonin/noradrenaline reuptake inhibitors (long term). Efficacy, compliance, and acceptability are, however, far from ideal, reinforcing interest in alternative options. Agomelatine, clinically employed in the treatment of major depression, expresses anxiolytic properties in rodents and was effective in the treatment of GAD (including severely ill patients) in several double-blind, short-term (12 weeks) and relapse-prevention (6 months) studies. At active doses, the incidence of adverse effects was no higher than for placebo. Agomelatine possesses a unique binding profile, behaving as a melatonin (MT₁/MT₂) receptor agonist and 5-HT_2C receptor antagonist, yet recognizing neither monoamine transporters nor GABA_A receptors. Extensive evidence supports a role for 5-HT_2C receptors in the induction of anxious states, and their blockade likely plays a primary role in mediating the anxiolytic actions of agomelatine, including populations in the amygdala and bed nucleus of stria terminalis, as well as the hippocampus. Recruitment of MT receptors in the suprachiasmatic nucleus, thalamic reticular nucleus, and hippocampus appears to fulfil a complimentary role. Downstream of 5-HT_2C and MT receptors, modulation of stress-sensitive glutamatergic circuits and altered release of the anxiogenic neuropeptides, corticotrophin-releasing factor, and vasopressin, may be implicated in the actions of agomelatine. To summarize, agomelatine exerts its anxiolytic actions by mechanisms clearly distinct from those of other agents currently employed for the management of GAD.

Plain Language Summary

How agomelatine helps in the treatment of anxiety disorders

Introduction:

• Anxiety disorders have a significant negative impact on quality of life.

• The most common type of anxiety disorder, called generalized anxiety disorder (GAD), is associated with nervousness and excessive worry.

• These symptoms can lead to additional symptoms like tiredness, sleeplessness, irritability, and poor attention.

• GAD is generally treated through either cognitive-behavioural therapy or medication. However, widely used drugs like benzodiazepines and serotonin reuptake inhibitors have adverse effects.

• Agomelatine, a well-established antidepressant drug, has shown anxiety-lowering (‘anxiolytic’) properties in rats and has been shown to effectively treat GAD with minimal side effects.

• However, exactly how it acts on the brain to manage GAD is not yet clear.

• Thus, this review aims to shed light on agomelatine’s mechanism of action in treating GAD.

Methods:

• The authors reviewed studies on how agomelatine treats anxiety in animals.

• They also looked at clinical studies on the effects of agomelatine in people with GAD.

Results:

• The study showed that agomelatine ‘blocks’ a receptor in nerve cells, which plays a role in causing anxiety, called the 5-HT_2C receptor.

• Blocking this receptor, especially in specific brain regions such as nerve cells of the amygdala, bed nucleus of stria terminalis, and hippocampus, produced the anxiety reduction seen during agomelatine treatment.

• Agomelatine also activates the melatonin (MT) receptor, which is known to keep anxiety in check, promote sleep, and maintain the sleep cycle.

• Agomelatine should thus tackle sleep disturbances commonly seen in patients with GAD.

• Beyond 5-HT_2C and MT receptors, signalling molecules in nerve cells that are known to be involved in anxiety disorders (called ‘neurotransmitters’ and ‘neuropeptides’) are also affected by agomelatine.

Conclusion:

• Agomelatine’s anxiolytic effects are caused by mechanisms that are distinct from those of other medications currently used to treat GAD.

• This explains its therapeutic success and minimal adverse side effects.

Keywords

fear GABA glutamate melatonin receptor stress

Infographic

Video Abstract Please click on the image to play the video (also available as supplemental material).

Introduction: core features of GAD and its current treatment

Anxiety disorders are a diverse assemblage of conditions that have a serious and negative impact on quality of life. When diagnosed in children, adolescents, and young adults, they often persist into later life. The most common class of anxiety disorder is GAD, which unfortunately is becoming more prominent amid the current COVID pandemic.¹ Generalized anxiety disorder (GAD) is typically characterized by pervasive anxiety and nervousness, disproportionate worry, and over-generalization of genuine fear to neutral or ambivalent stimuli, sometimes on the basis of previous adverse experiences.^2–6 Distressing emotions and thoughts are difficult to control, persist over months, and are associated with symptoms like fatigue, insomnia, irritability, poor concentration, attentional deficits, and physical complaints. Accordingly, GAD disrupts social and familial relationships and interferes with work and daily activities. Furthermore, GAD is frequently comorbid with other anxious states like social phobia and also with dysthymia or frank depression.^2,5,7

Among a range of potential therapies, benzodiazepines are usually reserved for the immediate and acute (hours to days) control of GAD owing to the risk of dependence and a withdrawal syndrome, in addition to sedation and impairment of cognition.² First-line and long-term treatment is mainly oriented around cognitive-behavioural and relaxation techniques, as well as the administration of selective serotonin reuptake inhibitors (SSRIs) and serotonin/noradrenaline reuptake inhibitors (SNRIs).^2,8–14 In certain (rare) cases, the 5-HT1A partial agonist, buspirone, is prescribed.^2,14 Furthermore, the anti-epileptic/analgesic and gabapentoid, pregabalin, may sometimes be administered. However – especially in association with recreational drugs and in patients with substance-abuse disorders – it presents a risk of misuse and addiction, while potential, ion channel-mediated toxic actions should also not be neglected.^15–17 Where treatment-resistance or intolerance is encountered with standard medication, other agents may be considered such as the antidepressants, imipramine, mirtazapine, and trazodone, and (usually as adjuncts and in low doses) second-generation antipsychotics like olanzapine and quetiapine.^13,18

A broad range of agents acting via contrasting molecular substrates is, then, available for the control of GAD. However, they all possess disadvantages in terms of incomplete efficacy, irresponsive patients and undesirable secondary actions. For example, some patients cannot tolerate SSRIs and SNRIs, and hence do not properly comply with their prescription. These limitations underlie continuing efforts to find improved – and mechanistically distinct – medication for the treatment of GAD.^2,13,19–21

The present article focusses on one such agent, agomelatine (Figure 1). In the wake of early studies documenting its anxiolytic properties in rodents, clinical studies have found that agomelatine is efficacious in the treatment of GAD. Agomelatine possesses a distinctive binding profile/mode of action which can be related both to its therapeutic efficacy in GAD and to its comparatively good acceptability compared to other agents.

Figure 1.

Schematic overview of the dual molecular mechanism of action of agomelatine in relation to its influence upon behaviour and its clinical properties. Agomelatine was active in several, short-term (12-week) clinical GAD trials and in a 6-month relapse-prevention study, displaying good tolerance. It is likewise effective in major depression. Based on studies in major depression and healthy subjects, Agomelatine should improve circadian rhythms and sleep patterns in GAD patients.

Agomelatine as a novel and mechanistically distinct option for GAD

In 2009, agomelatine was launched in Europe for the treatment of major depressive episodes in adults, and it was progressively authorized for use in major depression across a suite of countries in Asia, Africa, Australasia, and South America. (At that time, the parent company Servier was not present in the United States: while now represented, the focus is on Oncology and Research). Agomelatine was the first antidepressant to be licenced that possesses a non-monoaminergic component of activity, its unique pharmacological profile comprising dual-antagonist properties at 5-HT_2C receptors as well as agonist properties at melatonin (MT)₁ and MT₂ receptors^22–25 (see further below). This pattern of binding differs from all other classes of antidepressant currently in use, and it is distinct to the aforementioned agents clinically employed to treat GAD. Furthermore, by contrast to benzodiazepines, agomelatine does not interact with either ortho or allosteric sites on GABA_A receptors. In addition, agomelatine does not bind to the gabapentin-responsive alpha2delta subunit of voltage-dependent Ca²⁺ channels. In contrast to buspirone, it is devoid of affinity for 5-HT_1A receptors and, in distinction to SSRIs and SNRIs, agomelatine does not recognize monoamine reuptake sites.^22,23,25

The first indications that agomelatine might be of use for the management of GAD (and anxious states in general) emerged from experimental work in rodents.²⁶ Potential therapeutic efficacy in GAD was subsequently assessed within the framework of controlled clinical trials over 2008 to 2018, and these observations constitute the basis for a dossier in preparation for submission to the appropriate Health Authorities.^27,28 These observations are consecutively summarized below and then its potential mechanisms of action are considered in greater detail.

Anxiolytic properties of agomelatine: actions in animal models

In recent years, considerable efforts have been made to ameliorate the validity of animal models of anxiety, both for characterization of the underlying pathophysiology and for the improved detection of novel anxiolytics: in parallel, several ‘translational’ initiatives have been undertaken for the improved appraisal of potential anxiolytic activity in human subjects.^29–38 Yet no specific animal model for GAD, a multidimensional and complex disorder, has to date been described.

On the contrary, an exaggerated response to fear is common in GAD patients^3,6 suggesting that conditioned fear procedures in rats may have significant construct value for GAD. It is, thus, of note that agomelatine robustly reduced the freezing response to a conditioned aversive stimulus in rats.³⁹ Agomelatine has also been evaluated in a suite of other paradigms mirroring diverse dimensions of anxious states. One example is a Vogel Conflict (approach-avoidance) procedure, whereby anxiolytic agents release a response for food or water suppressed by a mild punishment – independently of any potential influence upon appetite or nociceptive thresholds.⁴⁰ Another example is provided by active Social Interaction with an unknown conspecific:^26,41 this is of note because there is increasing interest in overlapping features and cellular substrates of GAD and social anxiety.^42,43 In these and certain other procedures of potential anxiolytic properties, agomelatine displayed robust efficacy, though it has not invariably proven active in elevated plus maze and conditioned ultrasonic vocalization (USV) procedures^{23,24,26,41,44,45} (Table 1). Where active, the anxiolytic actions of agomelatine are expressed both acutely and upon sustained (several weeks) administration.^22,23,26,44

Table 1.

Summary of studies exploring the respective roles of 5-HT_2C antagonist versus melatonin agonist properties in the anxiolytic actions of agomelatine in rodents.

Model	Vogel conflict	Geller conflict	Social interaction	Social defeat	Plus maze
Agomelatine alone	Yes	Yes	Yes	Yes	Yes/No
5-HT_2C antagonists	Yes	Yes	Yes	Not tested	No
Melatonin alone	No	No	No	Yes (partial)	Yes/No
MT antagonist vs. agomelatine	Not blocked	Not tested	Not blocked	Not tested	Blocked

MT, melatonin.

Agomelatine was compared to several selective 5-HT_2C antagonists and/or to melatonin under identical conditions. The activity of agomelatine in the social defeat model was abolished by ablation of the MT₁ receptor–rich suprachiasmatic nucleus. Variable results have been acquired with both agomelatine and melatonin in the elevated plus maze. In one study where agomelatine was effective, its actions were blunted by administration of the melatonin antagonist, S22153. This drug was likewise employed in interaction with agomelatine in the Vogel conflict and Social interaction procedures where it was, by contrast, inactive. For details, see main text.

Interestingly, agomelatine also counters anxiety-related behaviours in several rodent models of ‘depression’, including pre-natal or chronic stress.^23,46,47 These observations, together with its clinically proven antidepressant properties,²² support the use of agomelatine for helping patients with mixed anxious-depressive states^7,48 – a possibility yet to be formally addressed in dedicated clinical trials.

Anxiolytic properties of agomelatine: actions in clinical studies of GAD

In the wake of the encouraging experimental findings outlined above, clinical efficacy of agomelatine (25–50 mg/day) was evaluated in patients suffering from GAD. Efficacy versus placebo was demonstrated in three independent, double-blind, ‘short-term’ (12-week) studies that employed both the Hamilton Anxiety Scale as well as the Sheehan Disability Scale to monitor functional impairment.^49–51 The positive outcome of these respective studies was recently reprised by a pooled meta-analysis that underpinned evidence for robust efficacy both in alleviating symptoms and in enhancing global patient function.^27,28 Efficacy of agomelatine was comparable to the active control, escitalopram (an SSRI), and secondary analysis supported effectiveness in severe GAD (Hamilton Anxiety Scale > 21).^28,49–52 Although its precise onset of efficacy remains to be further characterized, clinical studies suggest activity within the 1–3 weeks after commencing administration in at least some patients.^28,49–52 A further study undertaken over 6 months demonstrated efficacy in preventing relapse.⁵³

Despite concerns from depressed patients about a dose-dependent (albeit low) risk of hepatotoxicity that necessitates control of liver function,^22,54 only a small percentage (1.8%) of patients in the short-term studies of GAD showed potentially significant increases in transaminases: there were no cases of liver disease and transaminase levels normalized after stopping administration in all patients. This issue obviously requires close future surveillance, but data in GAD are so far reassuring, and recent comparative analyses of agomelatine with other antidepressants in major depression reinforce this conclusion.^55–57 Furthermore, tolerance was good in GAD patients with no difference in the frequency of discontinuation-related adverse effects in the agomelatine (headache, nasopharyngitis, and nausea) versus placebo groups (both 2.1%). In addition, there was no evidence for an agomelatine withdrawal syndrome in either the short-term or relapse-prevention studies.^28,49–53 These observations are consistent with clinical observations acquired in studies of its antidepressant properties.^22,56 More specifically, they support the notion that the distinctive receptor-binding profile of agomelatine should not be associated with the risks of tolerance, dependence/withdrawal, and recreational abuse that burden benzodiazepines. Agomelatine lacks affinity for the 5-HT transporter,^22,23 and clinical work bears out the low risk of disrupted sexual function and sleep – or an acute exacerbation of anxiety – at the onset of treatment. This represents an important gain over SSRIs and SNRIs – and may also be an advantage compared with buspirone.^{13,22,23,27,28,57–62}

Activation of 5-HT_2C receptors, for example, on hypothalamic proopiomelanocortin neurons, suppresses appetite. Conversely, 5-HT_2C receptor blockade, in particular when coupled to histaminergic and/or muscarinic receptor antagonism, is a risk factor for increased food consumption, obesity, and metabolic dysregulation, as seen with numerous tricyclic antidepressants and ‘atypical’ antipsychotics like olanzapine.^63–68 It is of note, then, that agomelatine does not recognize histaminergic, muscarinic, or other classes of receptor incriminated in triggering weight gain.^22,23 In addition, agomelatine is a neutral antagonist rather than inverse agonist at 5-HT_2C receptors, so it is does not decrease 5-HT_2C receptor–mediated transmission to below ‘normal or default’ levels.^69,70 These characteristics suggest that agomelatine has a low risk of metabolic perturbation and obesity, an assertion underscored by clinical observations in studies of both GAD and major depression.^22,28 There is also a correspondingly low risk of rebound anxiety or a discontinuation syndrome at the end of treatment.^22,28,70,71

To recap, then, the distinctive 5-HT_2C antagonist/MT agonist receptor-binding profile of agomelatine can be related both to its therapeutic efficacy in GAD and to its good tolerance.^13,27,28,58 Its favourable clinical profile was recently underscored in two separate meta-analyses of a diversity of agents clinically evaluated for the treatment of GAD.^13,58 Nonetheless, for a more fine-grained and complete understanding of the mechanisms of action of agomelatine in the control of GAD, it is instructive to consider a suite of observations acquired mainly in rodents.

Anxiolytic actions of agomelatine: 5-HT_2C receptor blockade compared to MT agonist properties

As regards the mechanism of action of agomelatine in the expression of its anxiolytic actions, the primary focus has not surprisingly been on the respective role of 5-HT_2C as compared to MT receptors. Employing agomelatine-responsive anxiolytic procedures in rats, comparisons have been undertaken both to 5-HT_2C antagonists and to MT. In addition, interaction studies have been performed with the MT₁/MT₂ receptor antagonist, S22153.²³ The key observations acquired are depicted in Table 1 and briefly outlined below.

In a Vogel conflict procedure undertaken in mildly (overnight) water-deprived rats, the ability of agomelatine to disinhibit punished (weak electric shock on the spout) was mimicked under identical conditions by several different selective 5-HT_2C receptor antagonists, whereas MT was inactive.²⁶ Similar observations have been made employing the related Geller (mild food-deprivation) procedure.²³ In addition, S22153 failed to block the anxiolytic actions of agomelatine in these paradigms. Comparable results were obtained in a model of active social interaction between two unfamiliar rats presented to each other in an unfamiliar (open-field) environment.²⁶ These observations strongly suggest that 5-HT_2C receptor blockade is necessary and sufficient for the expression of anxiolytic properties in the above procedures. In a separate study, S22153 enhanced (for not entirely clear reasons) the suppressive influence of agomelatine upon USVs provoked by conditioned fear: re-exposure to an environment previously associated with an aversive stimulus. Conversely, in a study of the elevated plus maze, the anxiolytic actions of agomelatine were blunted by S22153.⁴¹

Taken together, these findings suggest a major role for 5-HT_2C receptor blockade in the anxiolytic actions of agomelatine. Supporting this assertion, its 5-HT_2C antagonist properties are expressed over a similar dose-range in several pharmacological models.²³ In addition to this preponderant role for 5-HT_2C receptor antagonist properties, there appears to be a complementary role for MT receptor agonism in the anxiolytic profile of agomelatine. Further evidence underpinning the respective roles of 5-HT_2C and MT receptors is outlined in the following sections.

Key role for 5-HT_2C receptors in the anxiolytic actions of agomelatine: supporting studies in rodents and humans

In the light of the above-discussed evidence that 5-HT_2C receptor antagonism participates in the anxiolytic actions of agomelatine, it is instructive to evoke studies undertaken in animals and in humans that underpin a role for 5-HT_2C receptor blockade in the relief of GAD and anxious states.

First, paralleling observations obtained in direct, side-by-side comparisons with agomelatine, diverse classes of 5-HT_2C receptor antagonist exert anxiolytic properties across a range of animal models. Conversely, 5-HT_2C receptor agonists generally display anxiogenic properties.^71–75 Second, in line with these findings, 5-HT_2C receptor knockout mice display an ‘anxious’ profile, though this is only seen under certain conditions and a tendency for increased locomotor activity complicates interpretation of data.^64,76,77 Third, indirect, 5-HT-mediated activation of 5-HT_2C receptors mediates the acute anxiogenic actions of SSRIs in rodents, notably in the social interaction procedure in which agomelatine is anxiolytic. Conversely, upon long-term exposure, this anxiogenic effect fades and 5-HT_2C receptor desensitization/down-regulation likely contributes to the long-term anxiolytic effects of SSRIs: studies of hippocampal electroencephalographic activity in rats reinforce this interpretation.^78–85 Fourth, second-line antidepressants and antipsychotics used to treat GAD (or their major metabolite in the case of quetiapine) share antagonist properties at 5-HT_2C receptors.^86–90 Finally, while no selective ligand at 5-HT_2C receptors has yet been authorized for the therapy of GAD, the 5-HT_2C antagonist ritanserin abrogates the exacerbation of anxiety in GAD patients provoked by the prototypical 5-HT_2C agonist, ‘mCPP’ (meta-chlorophenylpiperazine). Ritanserin also blocks the anxiogenic and other effects of mCPP in non-anxious (‘normal’) subjects.^91–93 Thus, both experimental and clinical evidence supports a role for 5-HT_2C receptor antagonism in the attenuation of anxious states and the relief of GAD by agomelatine.

Before moving on to MT receptors, it should be mentioned that agomelatine displays affinity comparable to that for 5-HT_2C receptors at closely related 5-HT_2B receptors: mCPP and ritanserin also interact with 5-HT_2B receptors.^23,63,94,95 In contrast to 5-HT_2C receptors, however, there is no evidence from either pharmacological or gene knockout studies that 5-HT_2B receptor activation elicits anxious states, nor that their inactivation is associated with anxiolytic properties. Indeed, as compared to 5-HT_2C receptors, several studies have reported that 5-HT_2B agonists rather than antagonists display anxiolytic actions.^48,70,96,97 Accordingly, there is no evidence for a role of 5-HT_2B blockade in the influence of agomelatine upon anxiety, and the discussion below focusses on 5-HT_2C receptors.

A complementary role for MT receptors in the anxiolytic actions of agomelatine: supporting studies in rodents and humans

As regards a complementary role for melatonergic agonism in the anxiolytic actions of agomelatine, supporting data are less broad-based than those for 5-HT_2C receptor blockade. Nonetheless, a few studies have reported anxiolytic actions of MT (as a function of the procedure and time of light cycle) in rodent models like the elevated plus maze and novelty suppressed feeding tests.^41,98–103 Most pertinently, in a paradigm of social defeat, agomelatine abrogated associated anxiety-related behaviours, and its actions were partially reproduced by MT (5-HT_2C antagonists were not unfortunately tested) and abolished by lesions of the MT₁ receptor–rich suprachiasmatic nucleus (SCN).⁴⁵ Furthermore, increases in anxiety have been documented in MT₁ knock mice.¹⁰⁴ As regards MT₂ receptors, the synthetic MT₂ agonist (UCM765) has been reported to mimic the anxiolytic properties of MT, and its actions were blocked by a selective MT₂ receptor antagonist.¹⁰² In line with this work, male and/or female mice genetically deprived of MT₂ receptors display enhanced anxiety.^105–108 As regards human subjects, data are very sparse, yet there is fragmentary evidence for anxiolytic effects of MT under specific conditions, such as pre-operative stress.^100,109

Independently of any direct influence of MT agonism on circuits mediating and controlling anxiety, MT receptor stimulation by agomelatine should be linked to an improvement (advanced onset) of sleep and circadian rhythms.^110,111 Since sleep is commonly perturbed in patients with GAD, this would be expected to favour the relief of anxious states.^5,7,35

Cerebral loci of action of agomelatine in relation to fear-anxiety integrating circuits

The above observations focussed on the significance of the primary molecular targets of agomelatine, 5-HT_2C and MT receptors, in the expression of its anxiolytic properties. Two interrelated questions arise. First, regarding the cerebral location of the respective populations of receptor involved and, second, concerning the roles of various downstream neurotransmitters and neuromodulators in mediating the 5-HT_2C/MT receptor–triggered actions of agomelatine. Figure 2 presents an overview of our current knowledge in this respect which serves as a framework for the discussion below, and for future work.

Figure 2.

Schematic illustration of cerebral structures and neuromediators potentially involved in the anxiolytic actions of agomelatine in relation to the localization of 5-HT_2C and MT₁ receptors. Several interconnected structures integrating fear and anxiety are shown. Both the thalamic reticular nucleus (TRN)–via the mediodorsal thalamus–as well as the ventral hippocampus project to the frontal cortex (FCX). The FCX itself innervates the bed nucleus of the stria terminalis (BNST) and the amygdala, the latter of which also projects to the BNST (Adhikari, 2014). The interlinked amygdala and BNST represent key sites for the expression of fear and anxiety. 5-HT_2C and MT₁ or MT₂ receptors in these regions are likely sites for anxiolytic actions of agomelatine, which is thought to act via the neural mechanisms indicated. Other potential sites of action for agomelatine include the habenula, the dorsal striatum and the periaqueductal grey (not shown, see main text). Agomelatine may also act at MT₁ sites in the SCN (directly or via modulation of circadian rhythms) to affect anxious states, and via modulation of the secretion of vasopressin/oxytocin from paraventricular/supra-optic nuclei, likely downstream of 5-HT_2C receptors. This figure represents a work in progress: further study is needed to more precisely determine the cellular and neural mechanisms of anxiolytic action of agomelatine in GAD.

Comparatively, few studies have to date been undertaken with agomelatine to specifically identify its anxiolytic loci of action in the brain. One pragmatic reason for this is the highly lipophilic nature of agomelatine, leading to rapid diffusion through neural tissue: this renders intracerebral microinjection studies problematic. Nonetheless, a functional magnetic resonance imaging (fMRI) study in rats found that agomelatine blocked the ‘BOLD’ response to a selective 5-HT_2C agonist (RO-60,0175) in the mediodorsal thalamus as well as the cortex, ventral hippocampus and periaqueductal grey,¹¹² key structures involved in the processing of fear and anxiety in animals and humans.^6,35,113,114 These findings support a role for 5-HT_2C receptors in the hippocampus in the anxiolytic actions of agomelatine. Interestingly, systemic administration of agomelatine exerts a marked influence on synaptic plasticity, diverse intracellular signals, and neuromodulators like neural cell adhesion molecule, an emotion-regulating growth factor, in this structure.^23,115,116 Findings with selective 5-HT_2C receptor agonists and antagonists underscore a role of the hippocampus in the modulation of anxiety, and they also provide evidence for roles of 5-HT_2C receptors in the amygdala (basolateral and central nuclei) and the interconnected bed nucleus of the stria terminalis (BNST). For example, activation of 5-HT_2C receptors in the basolateral amygdala underlies the induction of anxiety by stimulation of the raphe nucleus.¹¹⁷ These regions comprise core elements of a stress-sensitive, fear-integrating circuit involved in the induction of anxious states that is modulated by 5-HT_2C receptors and, ipso facto, one may assume agomelatine^{48,63,64,84,118–121} (see also next section).

Like 5-HT_2C receptors, both MT₁ and MT₂ receptors are localized in the hippocampus (mainly dental gyrus and CA3 regions, respectively). The former are also highly concentrated in the SCN, whereas the latter are prominent in the thalamic reticular nucleus (TRN).¹²² As mentioned above, the approach of discrete brain lesions suggests that the integrity of the MT₁ receptor-enriched SCN, the circadian master regulator, is required for alleviation by agomelatine of anxious behaviour following social defeat.⁴⁵ Agomelatine interacts with circadian-rhythm-related genes (like ‘Period-1’) in the SCN (and hippocampus): studies are undergoing to determine if and how this influence relates to specific classes of anxiety disorders.^123,124 On the contrary, the above-mentioned MT₂ receptor agonist UCM765 activates neurons in the TRN that project via the dorsal medial thalamus to the frontal cortex (FCX), which itself feeds into the amygdala-BNST axis to control anxious states. Accordingly, it has been proposed that activation of MT₂ receptors in the TRN acts via this neural cascade to counter anxiety, and they are a potential substrate for the anxiolytic actions of agomelatine.^102,108,125 This possibility is especially interesting bearing in mind the role of the TRN in sleep¹²⁶ and evidence that agomelatine influences the activity of neurons in the dorsomedial thalamus and FCX downstream of the TRN.^23,112 Finally, a role of either MT₁ and/or MT₂ receptors in the hippocampus may, by analogy to their 5-HT_2C counterparts, be involved in the response to stress and the anxiolytic actions of MT together with, by extrapolation, agomelatine.^{23,100,103,127}

Potential neurochemical substrates of action involved in the anxiolytic actions of agomelatine

As regards neurochemical substrates involved in the anxiolytic properties of agomelatine, it is interesting to consider potential roles for glutamate and several different classes of neuropeptide.

Both 5-HT_2C receptor ligands and SSRIs have been found to impact stress-sensitive glutamatergic transmission in structures like the FCX, hippocampus, and amygdala.^128,129 As regards agomelatine itself, its acute administration blunted stress-induced release of glutamate in the basolateral and central amygdala as well as the hippocampus. In the past, the tendency has been to automatically relate this modulation of glutamatergic pathways (and other neurochemical effects of agomelatine) to its antidepressant actions. However, these effects might more compellingly be interlinked with its anxiolytic properties in view of the pivotal role of the amygdala and hippocampus in the regulation of fear and anxiety.^{35,46–48,113,114}

Modulation of the activity of the anxiogenic peptide, corticotrophin-releasing factor (CRF) in the amygdala and the BNST^35,130,131 has been implicated in the influence of 5-HT_2C receptors – and, by extension, agomelatine – upon anxious states.^{35,82,117,121,132} Of particular interest, serotonergic pathways projecting to the BNST from the dorsal raphe act via 5-HT_2C receptors to engage a CRF circuit that inhibits the anxiolytic influence of a BNST projection to the lateral hypothalamus and ventrotegmental area. Activation of these 5-HT_2C receptors by SSRIs is thought to underlie their aversive/anxiogenic effects at the onset of treatment. Agomelatine would act oppositely to SSRIs in blocking BNST-located 5-HT_2C sites and moderating CRF output, contributing to the expression of its anxiolytic properties in the absence of an early phase of aggravated anxiety.^2,13,28,121 CRF may not be the only neuropeptide potentially implicated in the actions of agomelatine. Post-weaning isolation in rats is associated with heightened anxiety in adults, together with reduced plasma levels of oxytocin (which possesses anxiolytic properties) and elevated levels of vasopressin (‘anxiogenic’).³⁵ Sub-chronic (2 weeks) administration of agomelatine moderated anxiety as well as reversing the increases in vasopressin levels, and (albeit only in females) it also attenuated the fall in levels of oxytocin.³³ These effects were specific since, despite the above-described influence on CRF in the BNST, there was no apparent influence on corticosterone levels downstream of the hypothalamic–pituitary–adrenal axis.¹³³ Intriguingly, there is evidence that 5-HT_2C receptors physically associate with and blunt signalling at oxytocin receptors and that oxytocin hypoactivity is countered by 5-HT_2C antagonists including, at least in theory, agomelatine.¹³⁴

Serotonergic projections are subject to the inhibitory control of GABAergic interneurons expressed both at the level of terminals and of cell bodies in raphe nuclei. Accordingly, benzodiazepines suppress (‘excess’) release of 5-HT by activation of GABA_A receptors presynaptic to serotonergic neurons in the dorsal raphe nucleus, hippocampus, amygdala, and other regions, actions that contribute to their anxiolytic properties.^{2,8,26,35,78,135} Interestingly, at least in rodents, 5-HT_2C receptors are expressed by raphe-localized GABAergic interneurons targeting serotonergic pathways projecting to the basolateral amygdala.¹³⁵ Under conditions of acute stress, 5-HT_2C agonists attenuate the activity of ascending serotonergic pathways^136,137 This action, and some – albeit inconsistent – evidence for anxiolytic properties of 5-HT_2C agonists, likely reflect recruitment of GABAergic interneurons upstream of serotonergic pathways.^{26,35,138,139} Nonetheless, presumably reflecting the low tonic activity of 5-HT_2C receptors on GABAergic neurons, as assessed by dialysis in freely moving rats and at anxiolytic doses, agomelatine did not modify extracellular levels of 5-HT in the hippocampus or other structures^5,26 (Figure 3). This lack of impact on extracellular levels of 5-HT mimics selective 5-HT_2C antagonists and distinguishes agomelatine both to benzodiazepines (decreased release of 5-HT)^26,78,140 and to SSRIs and SNRIs which elevate synaptic levels of 5-HT by blocking 5-HT reuptake sites on serotonergic terminals: increases are seen both acutely and upon long-term administration.^62,89 Agomelatine may also be contrasted in this respect to buspirone, which decreases extracellular levels of 5-HT in corticolimbic territories by recruitment of 5-HT_1A autoreceptors on raphe cell bodies.^35,140 In contrast to other classes of anxiolytic, then, agomelatine exerts its anxiolytic properties in the apparent absence of alterations in the release of 5-HT.

Figure 3.

Schematic depiction of the influence of agomelatine compared to several other classes of anxiolytic upon serotonergic/5-HT_2C receptor-mediated neurotransmission. A prototypical serotonergic neuron is shown, projecting onto a post-synaptic glutamatergic neuron in, for example, the hippocampus. Over-activation of 5-HT_2C receptors contributes to anxious states. Benzodiazepine’s recruit GABA_A receptors to reduce the release of 5-HT, yet these GABA_A receptors rapidly desensitize. Agents that block the reuptake of 5-HT by terminal-localized transporters (SERT) initially increase synaptic levels of 5-HT to stimulate 5-HT_2C receptors: upon long-term administration, in the face of sustained and high levels of 5-HT, 5-HT_2C receptors desensitize. agomelatine, by contrast, directly blocks 5-HT_2C receptors in both the short and long term.

Relationship of the anxiolytic properties of agomelatine to its antidepressant actions

Blockade of 5-HT_2C receptors and activation of MT receptors are the core mechanisms of action harnessed by agomelatine both in the treatment of GAD and, as amply discussed elsewhere, in the management of major depression.^22,23 Clearly, then, the anxiolytic and antidepressant actions of agomelatine are fully compatible, and they are expressed over similar dose-ranges in patients with GAD and major depression, respectively. Under conditions of comorbid GAD and depression, antidepressant and anxiolytic properties may mutually reinforce each other. Interestingly, furthermore, relief of anxious states may help hinder the course to major depression.¹⁴¹ Although formal trials remain to be performed, these elements, combined with the ability of agomelatine to counteract the anxiety associated with chronic stress in rats (vide supra) suggest that it should relieve ‘mixed’ anxio-depressive conditions in patients.^7,22,48

Noting interconnections between the anxiolytic and antidepressant actions of agomelatine is not, however, to contend that the same populations of 5-HT_2C and MT receptors and the same downstream substrates are implicated. Indeed, the above-discussed neural mechanisms engaged by agomelatine in the relief of anxious states are unlikely to mediate its impact on major depression. Conversely, pivotal to the antidepressant actions of agomelatine is its enhancement of the activity of dopaminergic and adrenergic pathways projecting to the FCX. This effect is unrelated to the anxiolytic properties of agomelatine, despite a possible role for 5-HT_2C receptors in the FCX – interconnected with the amygdala-BNST.^{35,113,142,143}

General discussion: open questions and perspectives

Finally, additional study should provide further insights into the mechanisms of action of agomelatine in the treatment of GAD.

First, at the cellular level, by analogy to 5-HT_2C receptor-Oxytocin receptor heterodimers (vide supra), a physical interaction between 5-HT_2C and MT₂ receptors has been demonstrated both in cellular expression systems, as well as the hippocampus and cortex of rats.^144,145 5-HT_2C-MT₂ functional heterodimers possess ligand recognition and coupling properties that differ from the constituent monomers and dimers. Since agomelatine potently recognizes these heterodimers, it has been speculated that they may be involved in the clinical actions of agomelatine in depression. The same might be contended for GAD. However, while there is increasing evidence for the relevance of heteromeric G-protein-coupled receptor (GPCR) complexes to central nervous sytem (CNS) disorders,^146,147 it is not yet known whether 5-HT_2C-MT₂ heterodimers are affected in the brain of GAD patients, nor whether their activity is altered under conditions of stress. Furthermore, ligands highly selective for 5-HT_2C-MT₂ heterodimers versus constituent monomers would be needed to rigorously evaluate their functional significance. Such agents are being sought but have not yet been described.¹⁴⁵

Second, at the neurochemical and network level, it would be interesting to determine whether other neuromediators interlinked with 5-HT_2C receptors and known to influence anxious states, like cannabinoids and Neuropeptide Y, are involved in the actions of agomelatine.^148–150 Furthermore, induction of brain-derived neurotrophic factor (and neurogenesis) in the hippocampus and FCX has been related to the antidepressant actions of agomelatine – and many other antidepressants – and it may be more generally involved in the response to stress and anxious states.^{23,115,150–152}. Interestingly, 5-HT_2C receptor knockout mice reveal increased expression of brain-derived neurotrophic factor in the hippocampus.¹⁵³ It would also be insightful to acquire a clearer picture of the neural structures where agomelatine exerts its actions, exploiting both animal models and human subjects. In addition to the amygdala-BNST, the hippocampus and the FCX (Figure 2), other structures warrant investigation such as the GAD-implicated habenula.³ In this MT receptor–rich structure,¹²³ 5-HT_2C receptors play a role in the control of anxiety.^122,154,155 5-HT_2C receptors localized in the dorsal striatum also participate in the induction of anxious states.^118,156 A final structure worth citing that possesses both MT receptors and 5-HT_2C receptors is the periaqueductal grey: this midbrain region is involved in the triggering of anxiety and has been identified as a site of action of 5-HT_2C antagonists.^{6,122,157,158} In addition to animal studies, clarification of neural circuits involved in the anxiolytic actions of agomelatine could be attempted in human subjects. This enterprise is however complicated – notwithstanding the sustained efforts of many laboratories – by the lack of specific positron emission tomography (PET)-imaging ligands.¹⁵⁹ An alternative approach, highlighted by work in rodents, would be fMRI and electroencephalographic strategies for exploring circuits involved in the relief of GAD by agomelatine in comparison to other classes of agent.^{85,108,112,160}

Third, the anxiolytic effects of agomelatine are expressed principally via 5-HT_2C receptors and ‘directly’ in interaction with corticolimbic and other subcortical circuits controlling anxious states. Nonetheless, in a clinical context, a beneficial influence of agomelatine on sleep patterns quality and circadian rhythms would be helpful in the relief of GAD and the improvement of quality of life. The influence of agomelatine upon sleep onset and rhythms is mainly melatonergic (MT receptor stimulation) in nature,^161–163 but a contribution of 5-HT_2C receptor blockade should not be neglected.^{85,110,111,164} In fact, blockade of 5-HT_2C receptors likely contributes to the short-term improvement by antidepressants like trazodone and mirtazapine of sleep, although their sedative properties – due to histamine H₁ antagonism – become problematic in some patients.^48,165,166 Conversely, an influence upon sleep of agomelatine (which possesses neither affinity for H₁ receptors nor marked sedative properties) does not play a major role in its antidepressant properties.^{22,110,165,166} Hence, to answer the question of whether – and by which mechanisms – a positive influence of agomelatine upon sleep and daily cycles putatively contributes to its relief of GAD, dedicated studies in patients will be required.^{22,28,165,167}

Fourth, since agomelatine has only been evaluated in adult populations for the relief of GAD, it would be of interest to examine its potentially beneficial influence on GAD in specific populations like the young, including children and adolescents. Finally, in view of positive results in tests of social interaction in rodents⁴⁸ and the social dimension of GAD,¹⁶⁴ clinical studies of Social Anxiety Disorder and specific types of social phobia would be of interest

Finally, agomelatine is currently the only clinically authorized compound to possess a co-joint 5-HT_2C receptor antagonist plus MT₁/MT₂ agonist profile. Nonetheless, at least one new agent (GW117) with a comparable binding profile has recently been documented.¹⁶⁸ Furthermore, it would be interesting to explore complementary ‘multi-target’ classes of agent articulated around 5-HT_2C receptor antagonist and/or MT agonist profiles for their potential utility in the improved treatment of GAD and other classes of anxiety disorder.

Concluding comments

In conclusion, agomelatine expresses its therapeutic efficacy in GAD principally via its antagonist properties at 5-HT_2C receptors with MT₁/MT₂ agonism providing complementary anxiolytic properties. Its actions at these receptors are distributed across several brain structures like the hippocampus, amygdala-BNST, SCN, and TRN, and they are expressed in interaction with a suite of neurotransmitters and neuropeptides like glutamate, CRF, and vasopressin, but the precise underlying substrates await further clarification. Agomelatine displays a novel and fundamentally different mechanism of anxiolytic action as compared to all other classes of medication used to treat GAD, accounting for its clinical efficacy in the relative absence of deleterious actions.

Supplemental Material

sj-docx-1-tpp-10.1177_20451253221105128 – Supplemental material for Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action

Supplemental material, sj-docx-1-tpp-10.1177_20451253221105128 for Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action by Mark J. Millan in Therapeutic Advances in Psychopharmacology

Supplemental Material

sj-pdf-2-tpp-10.1177_20451253221105128 – Supplemental material for Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action

Supplemental material, sj-pdf-2-tpp-10.1177_20451253221105128 for Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action by Mark J. Millan in Therapeutic Advances in Psychopharmacology

Footnotes

Acknowledgements

The author would like to thank Brian Morris and Kevin Fone for helpful comments on the manuscript and Jean-Michel Rivet for help in the preparation of the figures.

Author contribution(s)

Mark J. Millan: Conceptualization; Formal analysis; Investigation; Writing – original draft; Writing – review & editing.

ORCID iD

Mark J. Millan

Funding

The author received no financial support for the research, authorship, and/or publication of this article.

Conflict of interest statement

The author declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The author was until 2020 an employee of Institute de recherche Servier and participated in the discovery, characterization, and development of agomelatine for the treatment both of major depression and GAD. This review was written upon invitation by the Institute International de recherche de Servier, from whom the author received financial compensation.

Supplemental material

Supplemental material for this article is available online.

References

Barzilay

Moore

Greenberg

, et al Resilience, COVID-19-related stress, anxiety and depression during the pandemic in a large population enriched for healthcare providers. Transl Psychiatry 2020; 10: 291.

Craske

Stein

Eley

, et al Anxiety disorders. Nat Rev Dis Primers 2017; 3: 17024.

Huggins

Weis

Parisi

, et al Neural substrates of human fear generalization: a 7T-fMRI investigation. NeuroImage 2021; 239: 118308.

Lissek

Kaczkurkin

Rabin

, et al Generalized anxiety disorder is associated with overgeneralization of classically conditioned fear. Biol Psychiatry 2014; 75: 909–915.

Tyrer

Baldwin

. Generalised anxiety disorder. Lancet 2006; 368: 2156–2166.

Webler

Berg

Fhong

, et al The neurobiology of human fear generalization: meta-analysis and working neural model. Neurosci Biobehav Rev 2021; 128: 421–436.

Goodwin

Stein

. Generalised anxiety disorder and depression: contemporary treatment approaches. Adv Ther 2021; 38(Suppl. 2): 45–51.

Reinhold

Rickels

. Pharmacological treatment for generalized anxiety disorder in adults: an update. Expert Opin Pharmacother 2015; 16: 1669–1681.

Slee

Nazareth

Bondaronek

, et al Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet 2019; 393: 768–777.

10.

Carl

Miller

Henry

, et al Efficacy of digital cognitive behavioral therapy for moderate-to-severe symptoms of generalized anxiety disorder: a randomized controlled trial. Depress Anxiety 2020; 37: 1168–1178.

11.

Carpenter

Andrews

Witcraft

, et al Cognitive behavioral therapy for anxiety and related disorders: a meta-analysis of randomized placebo-controlled trials. Depress Anxiety 2018; 35: 502–514.

12.

Chen

Huang

Hsu

, et al Pharmacological and psychological interventions for generalized anxiety disorder in adults: a network meta-analysis. J Psychiatr Res 2019; 118: 73–83.

13.

Reinhold

Mandos

Rickels

, et al Pharmacological treatment of generalized anxiety disorder. Expert Opin Pharmacother 2011; 12: 2457–2467.

14.

Strawn

Geracioti

Rajdev

, et al Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert Opin Pharmacother 2018; 19: 1057–1070.

15.

Bonnet

Scherbaum

. How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol 2017; 27: 1185–1215.

16.

Evoy

Peckham

Covvey

, et al Gabapentinoid pharmacology in the context of emerging misuse liability. J Clin Pharmacol 2021; 61(Suppl. 2): S89–S99.

17.

Patel

Dickenson

. Mechanisms of the gabapentinoids and α 2 δ-1 calcium channel subunit in neuropathic pain. Pharmacol Res Perspect 2016; 4: e00205.

18.

Maneeton

Woottiluk

, et al Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther 2016; 10: 259–276.

19.

Bui

King

Melaragno

. Pharmacotherapy of anxiety disorders in the 21st century: a call for novel approaches. Gen Psychiatr 2019; 32: e100136.

20.

Schanzer

Rivas-Grajales

Khan

, et al Novel investigational therapeutics for generalized anxiety disorder (GAD). Expert Opin Investig Drugs 2019; 28: 1003–1012.

21.

Sonmez

Almorsy

Ramsey

, et al Novel pharmacological treatments for generalized anxiety disorder: pediatric considerations. Depress Anxiety 2020; 37: 747–759.

22.

de Bodinat

Guardiola-Lemaitre

Mocaër

, et al Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 2010; 9: 628–642.

23.

Guardiola-Lemaitre

De Bodinat

Delagrange

, et al Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties. Br J Pharmacol 2014; 171: 3604–3619.

24.

Konstantakopoulos

Dimitrakopoulos

Michalopoulou

. The preclinical discovery and development of agomelatine for the treatment of depression. Expert Opin Drug Discov 2020; 15: 1121–1132.

25.

Millan

Gobert

Lejeune

, et al The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306: 954–964.

26.

Millan

Brocco

Gobert

, et al Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology 2005; 177: 448–458.

27.

Stein

. Evidence-based pharmacotherapy of generalised anxiety disorder: focus on Agomelatine. Adv Ther 2021; 38(Suppl. 2): 52–60.

28.

Stein

Khoo

Picarel-Blanchot

, et al Efficacy of agomelatine 25-50 mg for the treatment of anxious symptoms and functional impairment in generalized anxiety disorder: a meta-analysis of three placebo-controlled studies. Adv Ther 2021; 38: 1567–1583.

29.

Bach

. Cross-species anxiety tests in psychiatry: pitfalls and promises. Mol Psychiatry 2022; 27: 154–163.

30.

Bourin

. Experimental anxiety model for anxiety disorders: relevance to drug discovery. Adv Exp Med Biol 2020; 1191: 169–184.

31.

Cryan

Sweeney

. The age of anxiety: role of animal models of anxiolytic action in drug discovery. Br J Pharmacol 2011; 164: 1129–1161.

32.

Grillon

Ernst

. A way forward for anxiolytic drug development: testing candidate anxiolytics with anxiety-potentiated startle in healthy humans. Neurosci Biobehav Rev 2020; 119: 348–354.

33.

Hart

Bergner

Smolinsky

, et al Experimental models of anxiety for drug discovery and brain research. Methods Mol Biol 2016; 1438: 271–291.

34.

La-Vu

Tobias

Schuette

, et al To approach or avoid: an introductory overview of the study of anxiety using rodent assays. Front Behav Neurosci 2020; 14: 145.

35.

Millan

. The neurobiology and control of anxious states. Prog Neurobiol 2003; 70: 83–244.

36.

Dias

Bevilaqua

da Luz

, et al Hippocampal biomarkers of fear memory in an animal model of generalized anxiety disorder. Behav Brain Res 2014; 263: 34–45.

37.

Luyten

Vansteenwegen

van Kuyck

, et al Contextual conditioning in rats as an animal model for generalized anxiety disorder. Cogn Affect Behav Neurosci 2011; 11: 228–244.

38.

Treit

Engin

McEown

. Animal models of anxiety and anxiolytic drug action. Curr Top Behav Neurosci 2010; 2: 121–160.

39.

Diaz-Mataix

Mocaër

Seguin

, et al The antidepressant agomelatine reduces fear long term memory but not acquisition or short term expression of fear memories. Eur Psychiatry 2011; 26: 653–653.

40.

Millan

Brocco

. The Vogel conflict test: procedural aspects, gamma-aminobutyric acid, glutamate and monoamines. Eur J Pharmacol 2003; 463: 67–96.

41.

Papp

Litwa

Gruca

, et al Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav Pharmacol 2006; 17: 9–18.

42.

Karunakaran

Amemori

Balakrishnan

, et al Generalized and social anxiety disorder interactomes show distinctive overlaps with striosome and matrix interactomes. Sci Rep 2021; 11: 18392.

43.

Showraki

Brown

. Generalized anxiety disorder: revisited. Psychiatr Q 2020; 91: 905–914.

44.

Regenass

Möller

Harvey

. Studies into the anxiolytic actions of agomelatine in social isolation reared rats: role of corticosterone and sex. J Psychopharmacol 2018; 32: 134–145.

45.

Tuma

Strubbe

Mocaër

, et al Anxiolytic-like action of the antidepressant agomelatine (S 20098) after a social defeat requires the integrity of the SCN. Eur Neuropsychopharmacol 2005; 15: 545–555.

46.

Marrocco

Reynaert

Gatta

, et al The effects of antidepressant treatment in prenatally stressed rats support the glutamatergic hypothesis of stress-related disorders. J Neurosci 2014; 34: 2015–2024.

47.

Morley-Fletcher

Mairesse

Soumier

, et al Chronic agomelatine treatment corrects behavioral, cellular, and biochemical abnormalities induced by prenatal stress in rats. Psychopharmacology 2011; 217: 301–313.

48.

Millan

. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006; 110: 135–370.

49.

Stein

Ahokas

de Bodinat

. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28: 561–566.

50.

Stein

Ahokas

Jarema

, et al Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: a 12-week, double-blind, placebo-controlled study. Eur Neuropsychopharmacol 2017; 27: 526–537.

51.

Stein

Khoo

Ahokas

, et al 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder. Eur Neuropsychopharmacol 2018; 28: 970–979.

52.

Stein

Ahokas

Márquez

, et al Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study. J Clin Psychiatry 2014; 75: 362–368.

53.

Stein

Ahokas

Albarran

, et al Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. J Clin Psychiatry 2012; 73: 1002–1008.

54.

Freiesleben

Furczyk

. A systematic review of agomelatine-induced liver injury. J Mol Psychiatry 2015; 3: 4.

55.

Billioti de Gage

Collin

Le-Tri

, et al Antidepressants and hepatotoxicity: a cohort study among 5 million individuals registered in the French National Health Insurance Database. CNS Drugs 2018; 32: 673–684.

56.

Pladevall-Vila

Pottegård

Schink

, et al Risk of acute liver injury in agomelatine and other antidepressant users in four European countries: a cohort and nested case-control study using automated health data sources. CNS Drugs 2019; 33: 383–395.

57.

Cipriani

Furukawa

Salanti

, et al Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018; 391: 1357–1366.

58.

Kong

deng

Wan

, et al Comparative remission rates and yolerability of drugs for generalised anxiety disorder: a systematic review and network meta-analysis of double-blind randomized controlled trials. Front Pharmacol 2020; 11: 580858.

59.

Montejo

Majadas

Rizvi

, et al The effects of agomelatine on sexual function in depressed patients and healthy volunteers. Hum Psychopharmacol 2011; 26: 537–542.

60.

Pandi-Perumal

Trakht

Srinivasan

, et al The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives. World J Biol Psychiatry 2009; 10: 342–354.

61.

Rothmore

. Antidepressant-induced sexual dysfunction. Med J Aust 2020; 212: 329–334.

62.

Shelton

. Serotonin and norepinephrine reuptake inhibitors. Handb Exp Pharmacol 2019; 250: 145–180.

63.

Di Giovanni

De Deurwaerdère

. New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders. Pharmacol Ther 2016; 157: 125–162.

64.

Chagraoui

Thibaut

Skiba

, et al 5-HT2C receptors in psychiatric disorders: a review. Prog Neuropsychopharmacol Biol Psychiatry 2016; 66: 120–135.

65.

Gill

El-Halabi

, et al Antidepressant medications and weight change: a narrative review. Obesity 2020; 28: 2064–2072.

66.

Thomas

Dourish

Tomlinson

, et al The 5-HT(2C) receptor agonist meta-chlorophenylpiperazine (mCPP) reduces palatable food consumption and BOLD fMRI responses to food images in healthy female volunteers. Psychopharmacology 2018; 235: 257–267.

67.

Wold

Wild

Cunningham

, et al Targeting the 5-HT2C receptor in biological context and the current state of 5-HT2C receptor ligand development. Curr Top Med Chem 2019; 19: 1381–1398.

68.

Yao

Cui

, et al Central 5-HTR2C in the control of metabolic homeostasis. Front Endocrinol 2021; 12: 694204.

69.

Millan

Marin

Kamal

, et al The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT(2C) receptors. Int J Neuropsychopharmacol 2011; 14: 768–783.

70.

Millan

. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 2005; 60: 441–460.

71.

Wood

Reavill

Trail

, et al SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. Neuropharmacology 2001; 41: 186–199.

72.

Dekeyne

Mannoury

Cour

Gobert

, et al S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models. Psychopharmacology 2008; 199: 549–568.

73.

Harada

Aota

Inoue

, et al Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone. Eur J Pharmacol 2006; 553: 171–184.

74.

Kennett

Wood

Bright

, et al SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 1997; 36: 609–620.

75.

Ohyama

Kondo

Yamauchi

, et al Asenapine reduces anxiety-related behaviours in rat conditioned fear stress model. Acta Neuropsychiatr 2016; 28: 327–336.

76.

Heisler

Zhou

Bajwa

, et al Serotonin 5-HT(2C) receptors regulate anxiety-like behavior. Genes Brain Behav 2007; 6: 491–496.

77.

Nebuka

Ohmura

Izawa

, et al Behavioral characteristics of 5-HT(2C) receptor knockout mice: locomotor activity, anxiety-, and fear memory-related behaviors. Behav Brain Res 2020; 379: 112394.

78.

Dekeyne

Denorme

Monneyron

, et al Citalopram reduces social interaction in rats by activation of serotonin (5-HT)(2C) receptors. Neuropharmacology 2000; 39: 1114–1117.

79.

Demireva

Suri

Morelli

, et al 5-HT2C receptor blockade reverses SSRI-associated basal ganglia dysfunction and potentiates therapeutic efficacy. Mol Psychiatry 2020; 25: 3304–3321.

80.

Martin

Trigo

, et al 5-HT2C receptor desensitization moderates anxiety in 5-HTT deficient mice: from behavioral to cellular evidence. Int J Neuropsychopharmacol 2014; 18: pyu056.

81.

Millan

Girardon

Dekeyne

. 5-HT2C receptors are involved in the discriminative stimulus effects of citalopram in rats. Psychopharmacology 1999; 142: 432–434.

82.

Pelrine

Pasik

Bayat

, et al 5-HT2C receptors in the BNST are necessary for the enhancement of fear learning by selective serotonin reuptake inhibitors. Neurobiol Learn Mem 2016; 136: 189–195.

83.

Sarkar

Chachra

Vaidya

. Postnatal fluoxetine-evoked anxiety is prevented by concomitant 5-HT2A/C receptor blockade and mimicked by postnatal 5-HT2A/C receptor stimulation. Biol Psychiatry 2014; 76: 858–868.

84.

Vicente

Zangrossi

. Serotonin-2C receptors in the basolateral nucleus of the amygdala mediate the anxiogenic effect of acute imipramine and fluoxetine administration. Int J Neuropsychopharmacol 2012; 15: 389–400.

85.

Papp

Koncz

Kostyalik

, et al Acute 5-HT(2C) receptor antagonist SB-242084 treatment affects EEG gamma band activity similarly to chronic escitalopram. Front Pharmacol 2019; 10: 1636.

86.

Jensen

Rodriguiz

Caron

, et al N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsychopharmacology 2008; 33: 2303–2312.

87.

Meltzer

. Serotonergic mechanisms as targets for existing and novel antipsychotics. Handb Exp Pharmacol 2012; 212: 87–124.

88.

Millan

Brocco

Rivet

, et al S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents. J Pharmacol Exp Ther 2000; 292: 54–66.

89.

Millan

Gobert

Lejeune

, et al S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 2001; 298: 565–580.

90.

Sánchez

Hyttel

. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 1999; 19: 467–489.

91.

Bressa

Marini

Gregori

. Serotonin S2 receptors blockage and generalized anxiety disorders. A double-blind study on ritanserin and lorazepam. Int J Clin Pharmacol Res 1987; 7: 111–119.

92.

Ceulemans

Hoppenbrouwers

Gelders

, et al The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam. Pharmacopsychiatry 1985; 18: 303–305.

93.

Seibyl

Krystal

Price

, et al Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects. Psychiatry Res 1991; 38: 227–236.

94.

Cussac

Newman-Tancredi

Quentric

, et al Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols. Naunyn Schmiedebergs Arch Pharmacol 2002; 365: 242–252.

95.

Dekeyne

Girardon

Millan

. Discriminative stimulus properties of the novel serotonin (5-HT)2C receptor agonist, RO 60-0175: a pharmacological analysis. Neuropharmacology 1999; 38: 415–423.

96.

Duxon

Kennett

Lightowler

, et al Activation of 5-HT2B receptors in the medial amygdala causes anxiolysis in the social interaction test in the rat. Neuropharmacology 1997; 36: 601–608.

97.

Kennett

Trail

Bright

. Anxiolytic-like actions of BW 723C86 in the rat Vogel conflict test are 5-HT2B receptor mediated. Neuropharmacology 1998; 37: 1603–1610.

98.

Comai

Gobbi

. Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology. J Psychiatry Neurosci 2014; 39: 6–21.

99.

Golombek

Pévet

Cardinali

. Melatonin effects on behavior: possible mediation by the central GABAergic system. Neurosci Biobehav Rev 1996; 20: 403–412.

100.

Huang

Yang

. The melatonergic system in anxiety disorders and the role of melatonin in conditional fear. Vitam Horm 2017; 103: 281–294.

101.

Naranjo-Rodriguez

Osornio

Hernandez-Avitia

, et al Anxiolytic-like actions of melatonin, 5-metoxytryptophol, 5-hydroxytryptophol and benzodiazepines on a conflict procedure. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24: 117–129.

102.

Ochoa-Sanchez

Rainer

Comai

, et al Anxiolytic effects of the melatonin MT(2) receptor partial agonist UCM765: comparison with melatonin and diazepam. Prog Neuropsychopharmacol Biol Psychiatry 2012; 39: 318–325.

103.

Spasojevic

Stefanovic

Jovanovic

, et al Anxiety and hyperlocomotion induced by chronic unpredictable mild stress can be moderated with melatonin treatment. Folia Biol 2016; 62: 250–257.

104.

Weil

Hotchkiss

Gatien

, et al Melatonin receptor (MT1) knockout mice display depression-like behaviors and deficits in sensorimotor gating. Brain Res Bull 2006; 1568: 425–429.

105.

Liu

Clough

Dubocovich

. Role of the MT(1) and MT(2) melatonin receptors in mediating depressive- and anxiety-like behaviors in C3H/HeN mice. Genes Brain Behav 2017; 16: 546–553.

106.

Belloch

Beltrán

Venzala

, et al Primary role for melatonin MT(2) receptors in the regulation of anhedonia and circadian temperature rhythm. Eur Neuropsychopharmacol 2021; 44: 51–65.

107.

Comai

De Gregorio

Posa

, et al Dysfunction of serotonergic activity and emotional responses across the light-dark cycle in mice lacking melatonin MT(2) receptors. J Pineal Res 2020; 69: e12653.

108.

Thomson

Mitchell

Openshaw

, et al Mice lacking melatonin MT2 receptors exhibit attentional deficits, anxiety and enhanced social interaction. J Psychopharmacol 2021; 35: 1265–1276.

109.

Hansen

Halladin

Rosenberg

, et al Melatonin for pre- and postoperative anxiety in adults. Cochrane Database Syst Rev 2015; 2015: CD009861.

110.

Descamps

Rousset

Millan

, et al Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture. Psychopharmacology 2009; 205: 93–106.

111.

Quera-Salva

Lemoine

Guilleminault

. Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients. Hum Psychopharmacol 2010; 25: 222–229.

112.

Linnik

McKie

Stark

, et al P.1.c.014 The novel antidepressant, agomelatine, blocks cerebral 5HT2C receptors in vivo: a phMRI challenge study in rats. Eur Neuropsychopharmacol 2009; 19: S259.

113.

Adhikari

. Distributed circuits underlying anxiety. Front Behav Neurosci 2014; 8: 112.

114.

Maron

Nutt

. Biological markers of generalized anxiety disorder. Dialogues Clin Neurosci 2017; 19: 147–158.

115.

Boulle

Massart

Stragier

, et al Hippocampal and behavioral dysfunctions in a mouse model of environmental stress: normalization by agomelatine. Transl Psychiatry 2014; 4: e485.

116.

Conboy

Tanrikut

Zoladz

, et al The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats. Int J Neuropsychopharmacol 2009; 12: 329–341.

117.

Matthiesen

Mendes

Spiacci

Jr , et al Serotonin 2C receptors in the basolateral amygdala mediate the anxiogenic effect caused by serotonergic activation of the dorsal raphe dorsomedial subnucleus. J Psychopharmacol 2020; 34: 391–399.

118.

Greenwood

Strong

Loughridge

, et al 5-HT2C receptors in the basolateral amygdala and dorsal striatum are a novel target for the anxiolytic and antidepressant effects of exercise. PLoS ONE 2012; 7: e46118.

119.

Ladurelle

Gabriel

Viggiano

, et al Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC. Psychopharmacology 2012; 221: 493–509.

120.

Luo

Jiang

, et al Anxiolytic effects of 5-HT₁A receptors and anxiogenic effects of 5-HT₂C receptors in the amygdala of mice. Neuropharmacology 2012; 62: 474–484.

121.

Marcinkiewcz

Mazzone

D’Agostino

, et al Serotonin engages an anxiety and fear-promoting circuit in the extended amygdala. Nature 2016; 537: 97–101.

122.

Leong

Liang

, et al Melatonin receptors: distribution in mammalian brain and their respective putative functions. Brain Struct Funct 2017; 222: 2921–2939.

123.

Cohen

Zohar

Carmi

. Effects of agomelatine on behaviour, circadian expression of period 1 and period 2 clock genes and neuroplastic markers in the predator scent stress rat model of PTSD. World J Biol Psychiatry 2020; 21: 255–273.

124.

Koresh

Kozlovsky

Kaplan

, et al The long-term abnormalities in circadian expression of period 1 and period 2 genes in response to stress is normalized by agomelatine administered immediately after exposure. Eur Neuropsychopharmacol 2012; 22: 205–221.

125.

Ferguson

Gao

. Thalamic control of cognition and social behavior via regulation of gamma-aminobutyric acidergic signaling and excitation/inhibition balance in the medial prefrontal cortex. Biol Psychiatry 2018; 83: 657–669.

126.

Luppi

Fort

. Sleep-wake physiology. Handb Clin Neurol 2019; 160: 359–370.

127.

Wang

Cao

, et al Melatonin ameliorates anxiety-like behaviors induced by sleep deprivation in mice: role of oxidative stress, neuroinflammation, autophagy and apoptosis. Brain Res Bull 2021; 174: 161–172.

128.

Reagan

Reznikov

Evans

, et al The antidepressant agomelatine inhibits stress-mediated changes in amino acid efflux in the rat hippocampus and amygdala. Brain Res 2012; 1466: 91–98.

129.

Tardito

Milanese

Bonifacino

, et al Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways. BMC Neurosci 2010; 11: 68.

130.

Millan

Brocco

Gobert

, et al Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent. Neuropsychopharmacology 2001; 25: 585–600.

131.

Kehne

Cain

. Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models. Pharmacol Ther 2010; 128: 460–487.

132.

Neugebauer

. Contribution of corticotropin-releasing factor receptor 1 (CRF1) to serotonin receptor 5-HT(2C)R function in amygdala neurons in a neuropathic pain model. Int J Mol Sci 2019; 20: 4380.

133.

Harvey

Regenass

Dreyer

, et al Social isolation rearing-induced anxiety and response to agomelatine in male and female rats: role of corticosterone, oxytocin, and vasopressin. J Psychopharmacol 2019; 33: 640–646.

134.

Chruścicka

Cowan

CSM

Wallace Fitzsimons

, et al Molecular, biochemical and behavioural evidence for a novel oxytocin receptor and serotonin 2C receptor heterocomplex. Neuropharmacology 2021; 183: 108394.

135.

Spoida

Masseck

Deneris

, et al Gq/5-HT2c receptor signals activate a local GABAergic inhibitory feedback circuit to modulate serotonergic firing and anxiety in mice. Proc Natl Acad Sci USA 2014; 111: 6479–6484.

136.

Martin

Gassmann

Chevarin

, et al Effect of genetic and pharmacological blockade of GABA receptors on the 5-HT2C receptor function during stress. J Neurochem 2014; 131: 566–572.

137.

Mongeau

Martin

Chevarin

, et al 5-HT2C receptor activation prevents stress-induced enhancement of brain 5-HT turnover and extracellular levels in the mouse brain: modulation by chronic paroxetine treatment. J Neurochem 2010; 115: 438–449.

138.

Craige

Lewandowski

Kirby

, et al Dorsal raphe 5-HT(2C) receptor and GABA networks regulate anxiety produced by cocaine withdrawal. Neuropharmacology 2015; 93: 41–51.

139.

Sant’Ana

Vilela-Costa

Vicente

, et al Role of 5-HT2C receptors of the dorsal hippocampus in the modulation of anxiety- and panic-related defensive responses in rats. Neuropharmacology 2019; 148: 311–319.

140.

Millan

Hjorth

Samanin

, et al S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties. J Pharmacol Exp Ther 1997; 282: 148–161.

141.

Anyan

Worsley

Hjemdal

. Anxiety symptoms mediate the relationship between exposure to stressful negative life events and depressive symptoms: a conditional process modelling of the protective effects of resilience. Asian J Psychiatr 2017; 29: 41–48.

142.

Kenwood

Kalin

Barbas

. The prefrontal cortex, pathological anxiety, and anxiety disorders. Neuropsychopharmacology 2022; 47: 260–275.

143.

Santana

Artigas

. Expression of serotonin2C receptors in pyramidal and GABAergic neurons of rat prefrontal cortex: a comparison with striatum. Cereb Cortex 2017; 27: 3125–3139.

144.

Gerbier

Ndiaye-Lobry

Martinez

Morentin

, et al Pharmacological evidence for transactivation within melatonin MT(2) and serotonin 5-HT(2C) receptor heteromers in mouse brain. FASEB J 2021; 35: e21161.

145.

Kamal

Gbahou

Guillaume

, et al Convergence of melatonin and serotonin (5-HT) signaling at MT2/5-HT2C receptor heteromers. J Biol Chem 2015; 290: 11537–11546.

146.

Borroto-Escuela

Carlsson

Ambrogini

, et al Understanding the role of GPCR heteroreceptor complexes in modulating the brain networks in health and disease. Front Cell Neurosci 2017; 11: 37.

147.

Gurevich

. GPCR signaling regulation: the role of GRKs and arrestins. Front Pharmacol 2019; 10: 125.

148.

Bogáthy

Kostyalik

Petschner

, et al Blockade of serotonin 2C receptors with SB-242084 moderates reduced locomotor activity and rearing by cannabinoid 1 receptor antagonist AM-251. Pharmacology 2019; 103: 151–158.

149.

Bonn

Schmitt

Lesch

, et al Serotonergic innervation and serotonin receptor expression of NPY-producing neurons in the rat lateral and basolateral amygdaloid nuclei. Brain Struct Funct 2013; 218: 421–435.

150.

Garakani

Murrough

Freire

, et al Pharmacotherapy of anxiety disorders: current and emerging treatment options. Focus (Am Psychiatr Publ) 2020; 19: 222–242.

151.

McIntyre

, et al Agomelatine-induced modulation of brain-derived neurotrophic factor (BDNF) in the rat hippocampus. Life Sci 2018; 210: 177–184.

152.

Sah

Schmuckermair

Sartori

, et al Anxiety- rather than depression-like behavior is associated with adult neurogenesis in a female mouse model of higher trait anxiety- and comorbid depression-like behavior. Transl Psychiatry 2012; 2: e171.

153.

Hill

Murray

Halley

, et al Brain-derived neurotrophic factor expression is increased in the hippocampus of 5-HT(2C) receptor knockout mice. Hippocampus 2011; 21: 434–445.

154.

Mei

Shiwalkar

, et al Anxiety during alcohol withdrawal involves 5-HT2C receptors and M-channels in the lateral habenula. Neuropharmacology 2020; 163: 107863.

155.

Pobbe

Zangrossi

Jr.

The lateral habenula regulates defensive behaviors through changes in 5-HT-mediated neurotransmission in the dorsal periaqueductal gray matter. Neurosci Lett 2010; 479: 87–91.

156.

Strong

Christianson

Loughridge

, et al 5-hydroxytryptamine 2C receptors in the dorsal striatum mediate stress-induced interference with negatively reinforced instrumental escape behavior. Neuroscience 2011; 197: 132–144.

157.

Nunes-de-Souza

Rodgers

, et al 5-HT2 receptor activation in the midbrain periaqueductal grey (PAG) reduces anxiety-like behaviour in mice. Behav Brain Res 2008; 187: 72–79.

158.

Yamashita

de Bortoli

Zangrossi

Jr.

5-HT2C receptor regulation of defensive responses in the rat dorsal periaqueductal gray. Neuropharmacology 2011; 60: 216–222.

159.

Kim

Moon

Lee

, et al A potential PET radiotracer for the 5-HT(2C) receptor: synthesis and in vivo evaluation of 4-(3-[(18)F]fluorophenethoxy)pyrimidine. ACS Chem Neurosci 2017; 8: 996–1003.

160.

Kostyalik

Kátai

Vas

, et al Chronic escitalopram treatment caused dissociative adaptation in serotonin (5-HT) 2C receptor antagonist-induced effects in REM sleep, wake and theta wave activity. Exp Brain Res 2014; 232: 935–946.

161.

Kennaway

. What do we really know about the safety and efficacy of melatonin for sleep disorders? Curr Med Res Opin 2022; 38: 211–227.

162.

Laudon

Frydman-Marom

. Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders. Int J Mol Sci 2014; 15: 15924–15950.

163.

Vasey

McBride

Penta

. Circadian rhythm dysregulation and restoration: the role of melatonin. Nutrients 2021; 13: 3480.

164.

Monti

Jantos

. The effects of systemic administration and local microinjection into the central nervous system of the selective serotonin 5-HT2C receptor agonist RO-600175 on sleep and wakefulness in the rat. Behav Pharmacol 2015; 26: 418–426.

165.

Tabarak

Wang

, et al Effects of agomelatine and mirtazapine on sleep disturbances in major depressive disorder: evidence from polysomnographic and resting-state functional connectivity analyses. Sleep 2020; 43: zsaa092.

166.

Wichniak

Wierzbicka

Walecka

, et al Effects of antidepressants on sleep. Curr Psychiatry Rep 2017; 19: 63.

167.

Moon

Partonen

Beaulieu

, et al Melatonergic agents influence the sleep-wake and circadian rhythms in healthy and psychiatric participants: a systematic review and meta-analysis of randomized controlled trials. Neuropsychopharmacology. Epub ahead of print 4 February 2022. DOI: 10.1038/s41386-022-01278.

168.

Gao

Zheng

Murezati

, et al GW117: a novel serotonin (5-HT2C) receptor antagonist and melatonin (MT1/MT2) receptor agonist with potential antidepressant-like activity in rodents. CNS Neurosci Ther 2021; 27: 702–713.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.08 MB

0.86 MB

Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action

Abstract

Plain Language Summary

Introduction:

Methods:

Results:

Conclusion:

Keywords

Introduction: core features of GAD and its current treatment

Agomelatine as a novel and mechanistically distinct option for GAD

Anxiolytic properties of agomelatine: actions in animal models

Anxiolytic properties of agomelatine: actions in clinical studies of GAD

Anxiolytic actions of agomelatine: 5-HT2C receptor blockade compared to MT agonist properties

Key role for 5-HT2C receptors in the anxiolytic actions of agomelatine: supporting studies in rodents and humans

A complementary role for MT receptors in the anxiolytic actions of agomelatine: supporting studies in rodents and humans

Cerebral loci of action of agomelatine in relation to fear-anxiety integrating circuits

Potential neurochemical substrates of action involved in the anxiolytic actions of agomelatine

Relationship of the anxiolytic properties of agomelatine to its antidepressant actions

General discussion: open questions and perspectives

Concluding comments

Supplemental Material

sj-docx-1-tpp-10.1177_20451253221105128 – Supplemental material for Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action

Supplemental Material

sj-pdf-2-tpp-10.1177_20451253221105128 – Supplemental material for Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action

Footnotes

Acknowledgements

Author contribution(s)

ORCID iD

Funding

Conflict of interest statement

Supplemental material

References

Supplementary Material

Anxiolytic actions of agomelatine: 5-HT_2C receptor blockade compared to MT agonist properties

Key role for 5-HT_2C receptors in the anxiolytic actions of agomelatine: supporting studies in rodents and humans